Status:
COMPLETED
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Lead Sponsor:
Andrei Iagaru
Collaborating Sponsors:
General Electric
Conditions:
Prostate Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
Detailed Description
Primary Objective: To evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer. Exploratory Objective: * Correlation of 68Ga PSMA 11 uptake a...
Eligibility Criteria
Inclusion
- Suspected prostate cancer
- Planned prostate biopsy
- Able to provide written consent
- Karnofsky performance status of 50 (or ECOG/WHO equivalent)
Exclusion
- Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam
- Metallic implants (contraindicated for MRI)
Key Trial Info
Start Date :
January 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 8 2022
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03809078
Start Date
January 14 2019
End Date
March 8 2022
Last Update
January 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94305